hig.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
GLP 1 secretion by microglial cells and decreased cns expression in obesity
Karolinska institutet.
Stockholms universitet, Institutionen för neurokemi.ORCID iD: 0000-0002-6668-1094
Karolinska institutet.
Stockholms universitet, Institutionen för neurokemi.ORCID iD: 0000-0002-0308-1964
Show others and affiliations
2012 (English)In: Journal of Neuroinflammation, E-ISSN 1742-2094, Vol. 9, article id 276Article in journal (Refereed) Published
Abstract [en]

Background: Type 2 diabetes (T2D) is a strong risk factor for developing neurodegenerative pathologies. T2D patients have a deficiency in the intestinal incretin hormone GLP-1, which has been shown to exert neuroprotective and anti-inflammatory properties in the brain. Methods: Here we investigate potential sources of GLP-1 in the CNS and the effect of diabetic conditions on the proglucagon mRNA expression in the CNS. The obese mouse model ob/ob, characterized by its high levels of free fatty acids, and the microglia cell line BV-2 were used as models. mRNA expression and protein secretion were analyzed by qPCR, immunofluorescence and ELISA. Results: We show evidence for microglia as a central source of GLP-1 secretion. Furthermore, we observed that expression and secretion are stimulated by cAMP and dependent on microglial activation state. We also show that insulin-resistant conditions reduce the central mRNA expression of proglucagon. Conclusion: The findings that microglial mRNA expression of proglucagon and GLP-1 protein expression are affected by high levels of free fatty acids and that both mRNA expression levels of proglucagon and secretion levels of GLP-1 are affected by inflammatory stimuli could be of pathogenic importance for the premature neurodegeneration and cognitive decline commonly seen in T2D patients, and they may also be harnessed to advantage in therapeutic efforts to prevent or treat such disorders.

Place, publisher, year, edition, pages
BMC , 2012. Vol. 9, article id 276
Keywords [en]
Glucagon-like peptide-1, Microglia, Neuroinflammation, Neuroprotection, Proglucagon
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:hig:diva-38206DOI: 10.1186/1742-2094-9-276ISI: 000314754300001OAI: oai:DiVA.org:hig-38206DiVA, id: diva2:1646298
Available from: 2013-03-20 Created: 2022-03-22 Last updated: 2024-07-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

Tracy, Linda M.Iverfeldt, KerstinSjöholm, Åke

Search in DiVA

By author/editor
Tracy, Linda M.Iverfeldt, KerstinSjöholm, Åke
In the same journal
Journal of Neuroinflammation
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 113 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf